Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 410-955-5000
Dr. Sampognaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Neuromuscular Medicine (Neurology), 2018 - 2019- University of California (San Francisco)Residency, Neurology, 2015 - 2018
Johns Hopkins University School of MedicineClass of 2014
Certifications & Licensure
CA State Medical License 2015 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- 4 citationsApilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro
Brain. 2024-09-03 - Correction: Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.Paul J Sampognaro, Shruti Arya, Giselle M Knudsen, Emma L Gunderson, Angelica Sandoval-Perez
Molecular Neurodegeneration. 2023-05-30 - 14 citationsMutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.Paul J Sampognaro, Shruti Arya, Giselle M Knudsen, Emma L Gunderson, Angelica Sandoval-Perez
Molecular Neurodegeneration. 2023-05-02
Grant Support
- TDP43 Degradation by the Lysosomal Proteases in Amyotrophic Lateral SclerosisUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
